Laura E. Niklason - 19 Nov 2024 Form 4 Insider Report for Humacyte, Inc. (HUMA)

Role
President, CEO and Director, Director
Signature
/s/ Laura E. Niklason by Dale A. Sander as Attorney-in-Fact
Issuer symbol
HUMA
Transactions as of
19 Nov 2024
Net transactions value
+$7,979
Form type
4
Filing time
21 Nov 2024, 07:31:17 UTC
Previous filing
20 Nov 2024
Next filing
20 Dec 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HUMA Common Stock Purchase $7,979 +1,797 +0.74% $4.44 243,851 19 Nov 2024 Direct F1, F2
holding HUMA Common Stock 1,148,240 19 Nov 2024 By The Niklason Living Trust
holding HUMA Common Stock 510,161 19 Nov 2024 By spouse
holding HUMA Common Stock 1,730,884 19 Nov 2024 By Ayabudge LLC
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This purchase is matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, against a portion of the sale by Ayabudge LLC, an entity controlled by the Reporting Person's spouse, of 809,786 shares of the Issuer's common stock on May 31, 2024. The Reporting Person has paid the Issuer $8,778.23, representing the full amount of profit realized in connection with this purchase.
F2 The price is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $4.435 to $4.4352. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.